Exelixis, Inc. (EXEL)

NasdaqGS • Currently up 0.86 (+1.25%) in today's trading session

1 member of Congress has disclosed 8 trades in Exelixis, Inc. (EXEL) via STOCK Act filings. The most recent disclosure was a sale by Donna E. Shalala on 4 June 2019. Aggregate disclosed activity totals roughly $32K in purchases and $32K in sales (midpoint estimates from bracketed disclosure amounts).

Exelixis, Inc. is currently trading at $69.57, positioned at 88% of its 52-week range ($39.71 – $73.69).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$69.57
24h Change
+0.86 (+1.25%)
52 Week Range
$39.71–$73.69
View on NASDAQ

Exelixis, Inc. Price History and Technical Analysis

Congressional Trading Activity for EXEL

Select to highlight on chart
5 transactions
Compliance: 50%
Donna E. Shalala4 Jun 201927 Apr 2020SaleStock$1,001 - $15,000N/A
Donna E. Shalala4 Jun 201921 Jul 2020SaleStock$1,001 - $15,000N/A
Donna E. Shalala16 Apr 201927 Apr 2020SaleStock$1,001 - $15,000N/A
Donna E. Shalala16 Apr 201921 Jul 2020SaleStock$1,001 - $15,000N/A
Donna E. Shalala6 Feb 201927 Apr 2020PurchaseStock$1,001 - $15,000N/A

See every trade

Sign in free to see the full trade history for this stock.

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$17.49B

Volume

2M

Beta

0.42

P/E Ratio

19.88

Fundamentals

EPS

$3.50

Div. Yield

-

Open

$68.50

Day Range

$68.01 – $70.32

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Michael Morrissey
IPO Date
2000-04-17
Website
www.exelixis.com

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available ther...

Earnings

Next Report

Q4 2026

9 Feb

EPS Est.

$0.96

Rev. Est.

$658.4M

Days Until

92

Recent Quarters

Q3 202629 Oct
EPS$0.94
Beat 6.0%
Q2 20265 Aug
EPS$0.91
Beat 6.7%
Q1 20265 May
EPS$0.87
Beat 13.7%
Q4 202510 Feb
EPS$0.94
Beat 22.1%
Q3 20254 Nov
EPS$0.78
Beat 13.9%
Q2 202528 Jul
EPS$0.75
Beat 15.4%
Q1 202513 May
EPS$0.62
Beat 73.1%
Q4 202411 Feb
EPS$0.55
Beat 7.8%
Q3 202429 Oct
EPS$0.40
Beat 14.3%
Q2 20246 Aug
EPS$0.77
Beat 156.7%
Q1 202430 Apr
EPS$0.17
Miss 39.3%
Q4 20236 Feb
EPS$0.27
Beat 28.6%
Q3 20231 Nov
EPS$0.10
Beat 0.0%
Q2 20231 Aug
EPS$0.25
Beat 56.3%
Q1 20239 May
EPS$0.12
Miss 20.0%
Q4 20227 Feb
EPS$-0.09
Beat 18.5%
Q3 20221 Nov
EPS$0.23
Beat 21.1%
Q2 20229 Aug
EPS$0.22
Beat 15.8%
Q1 202210 May
EPS$0.21
Beat 50.0%
Q4 202117 Feb
EPS$0.29
Beat 383.3%
Q3 20212 Nov
EPS$0.12
Miss 29.4%
Q2 20215 Aug
EPS$0.30
Beat 400.0%
Q1 20216 May
EPS$0.01
Q4 202010 Feb
EPS$0.09
Beat 80.0%
Q3 20205 Nov
EPS$-0.10
Miss 100.0%
Q2 20206 Aug
EPS$0.21
Beat 75.0%
Q1 20205 May
EPS$0.15
Beat 15.4%
Q4 201925 Feb
EPS$0.22
Beat 29.4%
Q3 201930 Oct
EPS$0.31
Beat 63.2%
Q2 201931 Jul
EPS$0.25
Beat 8.7%
Q1 20191 May
EPS$0.24
Beat 4.3%
Q4 201812 Feb
EPS$0.37
Beat 48.0%
Q3 20181 Nov
EPS$0.41
Beat 115.8%
Q2 20181 Aug
EPS$0.28
Beat 75.0%
Q1 20182 May
EPS$0.37
Beat 131.3%
Q4 201726 Feb
EPS$0.12
Beat 0.0%
Q3 20171 Nov
EPS$0.26
Beat 225.0%
Q2 20172 Aug
EPS$0.06
Beat 68.7%
Q1 20171 May
EPS$0.05
Beat 671.6%
Q4 201627 Feb
EPS$0.12
Beat 1900.0%
Q3 20163 Nov
EPS$0.01
Beat 107.7%
Q2 201630 Sept
EPS$-0.27
Q2 20163 Aug
EPS$-0.16
Beat 40.7%
Q1 20164 May
EPS$-0.27
Miss 8.0%
Q3 201510 Nov
EPS$-0.22
Miss 10.0%
Q2 201511 Aug
EPS$-0.22
Miss 4.8%
Q1 201530 Apr
EPS$-0.18
Beat 21.7%
Q4 201424 Feb
EPS$-0.30
Beat 3.2%
Q3 20144 Nov
EPS$-0.30
Beat 18.9%
Q2 201431 Jul
EPS$-0.38
Beat 2.6%
Q1 20141 May
EPS$-0.39
Miss 8.3%
Q4 201320 Feb
EPS$-0.38
Beat 0.0%
Q3 201330 Oct
EPS$-0.36
Beat 5.3%
Q2 20136 Aug
EPS$-0.34
Miss 13.3%
Q1 20137 May
EPS$-0.24
Beat 11.1%
Q4 201221 Feb
EPS$-0.24
Beat 0.0%
Q3 20127 Nov
EPS$-0.20
Beat 33.3%
Q2 20122 Aug
EPS$-0.25
Beat 7.4%
Q1 20123 May
EPS$-0.18
Miss 5.9%
Q4 20118 Feb
EPS$0.35
Beat 418.2%
Q3 201127 Oct
EPS$0.59
Beat 5.4%
Q2 20114 Aug
EPS$-0.16
Beat 5.9%
Q1 20113 May
EPS$-0.24
Miss 26.3%
Q4 201022 Feb
EPS$-0.16
Beat 20.0%
Q3 20104 Nov
EPS$-0.08
Miss 60.0%
Q2 20105 Aug
EPS$-0.21
Beat 0.0%
Q1 201011 May
EPS$-0.40
Miss 29.0%
Q4 20099 Mar
EPS$-0.27
Beat 0.0%
Q3 200929 Oct
EPS$-0.24
Beat 25.0%
Q2 200930 Jul
EPS$-0.42
Miss 2.4%
Q1 20097 May
EPS$-0.34
Miss 3.0%
Q4 20084 Mar
EPS$-0.36
Miss 2.9%
Q3 200827 Oct
EPS$-0.36
Beat 12.2%
Q2 20085 Aug
EPS$-0.43
Miss 4.9%
Q1 20086 May
EPS$-0.39
Miss 2.6%
Q4 200714 Feb
EPS$-0.19
Beat 34.5%
Q3 20075 Nov
EPS$-0.14
Beat 26.3%
Q2 20077 Aug
EPS$-0.29
Miss 3.6%
Q1 20073 May
EPS$-0.25
Beat 7.4%
Q4 200613 Feb
EPS$-0.27
Miss 8.0%
Q3 20062 Nov
EPS$-0.30
Beat 3.2%
Q2 20068 Aug
EPS$-0.29
Beat 3.3%
Q1 20069 May
EPS$-0.32
Miss 10.3%
Q4 200521 Feb
EPS$-0.29
Miss 3.6%
Q3 20053 Nov
EPS$-0.28
Beat 28.2%
Q2 20058 Aug
EPS$-0.13
Miss 160.0%
Q1 20059 May
EPS$-0.36
Beat 0.0%
Q4 200416 Feb
EPS$-0.35
Beat 7.9%
Q3 20048 Nov
EPS$-0.37
Beat 11.9%
Q2 20045 Aug
EPS$-0.37
Beat 2.6%
Q1 20044 May
EPS$-0.39
Beat 4.9%
Q4 200317 Feb
EPS$-0.32
Beat 8.6%
Q3 20035 Nov
EPS$-0.34
Beat 10.5%
Q2 20036 Aug
EPS$-0.40
Beat 4.8%
Q1 20037 May
EPS$-0.38
Beat 7.3%
Q4 200219 Feb
EPS$-0.34
Beat 15.0%
Q3 20027 Nov
EPS$-0.39
Beat 7.1%
Q2 20026 Aug
EPS$-0.39
Beat 4.9%
Q1 20026 May
EPS$-0.31
Beat 0.0%
Q4 200120 Mar
EPS$-0.26
Beat 18.8%
Q3 200113 Nov
EPS$-0.28
Beat 9.7%
Q2 20018 Aug
EPS$-0.30
Beat 3.2%
Q1 200114 May
EPS$-0.22
Beat 15.4%
Q4 200028 Feb
EPS$-0.18
Beat 10.0%
Q3 20008 Nov
EPS$-0.13
Beat 0.0%
Q2 20008 Aug
EPS$-0.16
Miss 23.1%
Q1 200015 May
EPS$-1.23

2 politicians traded within 30 days

No dividend data available for this stock.

No stock split data available for this stock.

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about EXEL

Which members of Congress have traded EXEL?
1 member of Congress has disclosed 8 trade in Exelixis, Inc. (EXEL) under the STOCK Act: Donna E. Shalala.
When was EXEL most recently disclosed by Congress?
The most recent EXEL disclosure was a sale by Donna E. Shalala on 4 June 2019.
What is the total disclosed congressional trading volume for EXEL?
Members of Congress have disclosed approximately $32K in EXEL purchases and $32K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in EXEL?
This EXEL page updates as soon as new STOCK Act disclosures are filed for Exelixis, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.